EN2-5. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in NSCLC without EGFR-activating mutations von Hidetoshi Hayashi, Conor E.Steuer, Wu-Chou Su, Makoto Nishio, Melissa L.Johnson, Dong-Wan Kim, Marianna Koczywas, Enriqueta Felip, Kathryn A.Gold, Haruyasu Murakami, Christina S.Baik, Sang-We Kim, Egbert F.Smit, Mark Gigantone, Ben Kim, Pang-Dian Fan, Zhenhao Qi, Elaine Y.Wu, David Sternberg, Pasi A.Janne

Volltext